270 related articles for article (PubMed ID: 27878207)
41. Von Willebrand factor-specific antibodies developing upon treatment of FVIII-deficient mice with different FVIII preparations.
Kallas A; Kuuse S; Maimets T; Pooga M
Acta Haematol; 2008; 119(4):244-7. PubMed ID: 18594135
[No Abstract] [Full Text] [Related]
42. Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products.
Rota M; Cortesi PA; Steinitz-Trost KN; Reininger AJ; Gringeri A; Mantovani LG
Blood Coagul Fibrinolysis; 2017 Dec; 28(8):627-637. PubMed ID: 28678027
[TBL] [Abstract][Full Text] [Related]
43. Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors.
van den Berg HM
Haemophilia; 2014 May; 20 Suppl 4():76-9. PubMed ID: 24762280
[TBL] [Abstract][Full Text] [Related]
44. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
Gringeri A; Musso R; Mazzucconi MG; Piseddu G; Schiavoni M; Pignoloni P; Mannucci PM;
Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
[TBL] [Abstract][Full Text] [Related]
45. Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors.
Jiménez-Yuste V; Oldenburg J; Rangarajan S; Kurth MH; Bozzo J; Santagostino E
Haemophilia; 2016 Jan; 22(1):e71-4. PubMed ID: 26612826
[No Abstract] [Full Text] [Related]
46. Immunogenicity of factor VIII concentrates in patients with hemophilia: a randomized clinical trial is warranted.
Gringeri A; Mannucci PM
Blood; 2007 Oct; 110(8):3084; author reply 3085. PubMed ID: 17916754
[No Abstract] [Full Text] [Related]
47. Novel therapies for immune tolerance in haemophilia A.
Collins PW
Haemophilia; 2006 Dec; 12 Suppl 6():94-100; discussion 100-1. PubMed ID: 17123401
[TBL] [Abstract][Full Text] [Related]
48. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
[TBL] [Abstract][Full Text] [Related]
49. A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies.
Santagostino E; Young G; Carcao M; Mannucci PM; Halimeh S; Austin S
Expert Rev Hematol; 2018 Feb; 11(2):87-97. PubMed ID: 29258406
[TBL] [Abstract][Full Text] [Related]
50. The burden of inhibitors in haemophilia patients.
Walsh CE; Jiménez-Yuste V; Auerswald G; Grancha S
Thromb Haemost; 2016 Aug; 116 Suppl 1():S10-7. PubMed ID: 27528280
[TBL] [Abstract][Full Text] [Related]
51. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.
Oldenburg J; Jiménez-Yuste V; Peiró-Jordán R; Aledort LM; Santagostino E
Haemophilia; 2014 Jan; 20(1):83-91. PubMed ID: 24354480
[TBL] [Abstract][Full Text] [Related]
52. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
Rothschild C; D'Oiron R; Borel-Derlon A; Gruel Y; Navarro R; Negrier C
Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
[TBL] [Abstract][Full Text] [Related]
53. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
Peyvandi F; Mannucci PM; Garagiola I; El-Beshlawy A; Elalfy M; Ramanan V; Eshghi P; Hanagavadi S; Varadarajan R; Karimi M; Manglani MV; Ross C; Young G; Seth T; Apte S; Nayak DM; Santagostino E; Mancuso ME; Sandoval Gonzalez AC; Mahlangu JN; Bonanad Boix S; Cerqueira M; Ewing NP; Male C; Owaidah T; Soto Arellano V; Kobrinsky NL; Majumdar S; Perez Garrido R; Sachdeva A; Simpson M; Thomas M; Zanon E; Antmen B; Kavakli K; Manco-Johnson MJ; Martinez M; Marzouka E; Mazzucconi MG; Neme D; Palomo Bravo A; Paredes Aguilera R; Prezotti A; Schmitt K; Wicklund BM; Zulfikar B; Rosendaal FR
N Engl J Med; 2016 May; 374(21):2054-64. PubMed ID: 27223147
[TBL] [Abstract][Full Text] [Related]
54. [Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].
Wu RH; Wei QQ
Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):631-4. PubMed ID: 24225299
[No Abstract] [Full Text] [Related]
55. Switching to low dose of plasma-derived factor VIII/vWF concentrates with Confact(®) -F as salvage immune tolerance induction in haemophilia A patients with inhibitors: five case reports from Japan.
Nagao A; Oka T; Hanabusa H
Haemophilia; 2015 Sep; 21(5):e425-7. PubMed ID: 25996457
[No Abstract] [Full Text] [Related]
56. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.
Strauss T; Lubetsky A; Ravid B; Bashari D; Luboshitz J; Lalezari S; Misgav M; Martinowitz U; Kenet G
Haemophilia; 2011 Jul; 17(4):625-9. PubMed ID: 21299743
[TBL] [Abstract][Full Text] [Related]
57. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S
Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
[TBL] [Abstract][Full Text] [Related]
58. Factor VIII products and inhibitor development in severe hemophilia A.
Gouw SC; van der Bom JG; Ljung R; Escuriola C; Cid AR; Claeyssens-Donadel S; van Geet C; Kenet G; Mäkipernaa A; Molinari AC; Muntean W; Kobelt R; Rivard G; Santagostino E; Thomas A; van den Berg HM;
N Engl J Med; 2013 Jan; 368(3):231-9. PubMed ID: 23323899
[TBL] [Abstract][Full Text] [Related]
59. Associations between type of product and inhibitors in previously untreated patients (PUPs) with severe hemophilia: switches and particular products can disturb analysis.
Calvez T; Laurian Y; Goudemand J
Blood; 2007 Aug; 110(3):1073-4; author reply 1074-5. PubMed ID: 17644742
[No Abstract] [Full Text] [Related]
60. Immune tolerance induction using a factor VIII/von Willebrand factor concentrate (BIOSTATE), with or without immunosuppression, in Australian paediatric severe haemophilia A patients with high titre inhibitors: a multicentre, retrospective study.
Robertson JD; Higgins P; Price J; Dunkley S; Barrese G; Curtin J
Thromb Res; 2014 Nov; 134(5):1046-51. PubMed ID: 25267706
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
